iBio (IBIO) Capital Expenditures (2012 - 2026)
iBio (IBIO) posted quarterly Capital Expenditures of $11000.0 for Q1 2026, down 21.43% year-over-year from $14000.0 in Q1 2025, and down 97.87% quarter-over-quarter from $516000.0 in Q4 2025.
iBio (IBIO) Capital Expenditures (2012 - 2026) Analysis & Trends
iBio (IBIO) has reported Capital Expenditures for 15 consecutive years, with $11000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 21.43% year-over-year to $11000.0; the TTM figure through Mar 2026 stood at $560000.0 (up 148.89% YoY), while the FY2025 annual figure was $16000.0, down 92.38% from the prior year.
- Capital Expenditures declined to $11000.0 in Q1 2026 per IBIO's latest filing, from $516000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.4 million in Q2 2022 and bottomed at -$201000.0 in Q1 2023.
- Historically, Capital Expenditures has averaged $815153.8 across 5 years, with a median of $210000.0 in 2024.
- Annual changes were most pronounced in 2023 — Capital Expenditures sank 131.21% — and 2025, when it soared 51500.0%.
- iBio's Capital Expenditures stood at $3.0 million in 2022, then plunged by 82.87% to $506000.0 in 2023, then sank by 99.8% to $1000.0 in 2024, then jumped by 51500.0% to $516000.0 in 2025, then slumped by 97.87% to $11000.0 in 2026.
- Business Quant data shows IBIO's Capital Expenditures at $11000.0 in Q1 2026, $516000.0 in Q4 2025, and $32000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,000.00 |
| Mar 31, 2026 | 11,000.00 |
| Dec 31, 2025 | 516,000.00 |
| Dec 31, 2025 | 516,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Jun 30, 2024 | 210,000.00 |
| Jun 30, 2024 | 210,000.00 |
| Jun 30, 2023 | 506,000.00 |
| Jun 30, 2023 | 506,000.00 |
| Mar 31, 2023 | -201,000.00 |
| Mar 31, 2023 | -201,000.00 |
| Dec 31, 2022 | 2.95 Mn |
| Dec 31, 2022 | 2.95 Mn |